First of all CARDARINE is is a PPARδ agonist and NOT a SARM. However they do work in similar ways. Cardarine is the ULTIMATE endurance solution, so bad WADA even has GW 501516 on their list of banned substances due to it's insane competitive edge. Expect great levels of intensity, forget about rest times, and break plateaus like never before. Some advantages of Cardarine: See results on first dose, Shred unnatural levels of fat without going catabolic, can be stacked with anything, Increase in Muscle Growth and Endurance. GW-501516 is really the jack of all trades for those experienced researchers.
This peptide is a modified fragment of hGH which contains the portion of the molecule that is believed to be responsible for hGH’s anti-obesity effects. The peptide has been shown to increase fat burning without the increase in blood sugar and growth rate that has been seen with hGH itself. AOD 9604 has been deemed safe for chronic use by the FDA, receiving Human GRAS status in 2014. In addition to its utility as an anti-obesity peptide, AOD 9604 has been shown to have very favorable cartilage repair and regenerative properties, especially when paired with peptide BPC 157.
In 1999, seven adult patients with GH deficiency and LV failure received hexarelin administrations. The GH response to hexarelin was negligible in these patients. Moreover, hexarelin administration increased their left ventricular ejection fraction (LVEF) without changing catecholamine levels, mean blood pressure (MBP), or cardiac output. For the first time, the acute administration of hexarelin proved to induce a positive inotropic effect in humans, which is GH independent and mediated by specific myocardial receptors for a GH secretagogue peptide.29 A subsequent study involving hexarelin administration to normal adults, severe GH-deficient patients (N = 7), and patients with severe ischemic DCM (N = 12) confirmed that the acute administration of hexarelin exerts a GH-independent positive inotropic effect likely mediated by specific GHRP myocardial receptors.30 This pioneering group subsequently evaluated the cardiac performances of the acute hexarelin administration (2.0 µg/kg, i.v.) in patients undergoing bypass surgery in comparison to patients given GH-releasing hormone, recombinant human GH, or placebo. The study concluded that the acute administration of hexarelin improved cardiac performance without any relevant variation in systemic vascular resistance and induced a reduction of wedge pressure and, significantly, that these cardiotropic effects were not shown by the other concurrent interventions.31

The impact of the treatment on the neodermal matrix reconstitution was qualitatively graded as described [17, 18]:(0)Immature granulation tissue with a null or incipient formation of collagen fibrils, focally distributed with no alignment and not organized meshwork. Fibrin material prevails in the field. Mallory staining is detected in scarce foci.(1)Scarce collagen fibrils suggestive of a primitive degree of organization, focally distributed, without horizontal alignment along the wound bed. Yet, fibrin occupies more than 50% of the field. Limited number of primitive neoformed vessels with empty lumen. Relative increase of positivity to Mallory staining.(2)A general but coarse image of ECM granulation tissue accumulation, containing intermixed vertically and horizontally oriented collagen fibrils. Full replacement of fibrin by collagen. Fibrin has been fully replaced by collagen. Affinity to Mallory staining is observed.(3)Complete ECM reconstitution, with mature and finely organized collagen fibrils horizontally deposited in the neodermis. The whole matrix appears positive to Mallory staining.
But gene-therapy experiments have also resulted in patient deaths. The use of such therapies can cause the human body to experience fatal immune reactions to the vectors used to place the gene in the body. Another danger of gene therapy is an inability to control the expression of the gene, which could translate into a rapidly spreading cancer. Or the expression of the gene could spread from skeletal muscle into heart muscle, resulting in excessive heart muscle growth (known as left ventricular hypertrophy, or “athlete’s heart) that can cause premature heart failure.
A SARM (an acronym for "Selective Androgen Receptor Modulator") is a drug that is chemically similar to anabolic steroids but with reduced androgenic properties. The main advantages SARMs have over anabolic steroids are androgen-receptor specificity, tissue selectivity, and reduced side effects. SARMs also have the ability to differentiate between anabolic and androgenic activities, whereas steroids do not.

As an athlete, you can also increase your dosage cycle for a period of 12 to 16 weeks at a time, to maximize your gains. Do so gradually if you opt to go this route. Make sure you increase your daily dosage (1 to 2 doses per day, etc.) gradually. Start off with lower dosage levels as well, and see how it interacts with your body. You don’t want to experience withdrawal, nor do you want to experience negative side effects when using Ipamorelin for longer dosage cycles. So, make sure you monitor your progress, see how you feel as you go, and make notes if/when you do experience negative side effects, so you can balance down to the proper dosage levels.
Dosing will ordinarily be at least twice per day and preferably 3x/day for best effect, taken at least 30-60 minutes before a meal and at a time of non-elevated blood sugar (in other words, after blood sugar has had time to fall since the most recent meal.) The amount taken generally will be from 50-300 mcg at a time. When using a GHRH along with GHRP-6, dosing should be reduced to 50-100 mcg at a time.

Figure 3.2 shows changes in intracellular calcium concentrations in several GHS-R-expressing cell lines as detected by fluorometric imaging plate reader (FLIPR)-based assays. Isolated GHS-R-expressing cell lines were activated by GHRP-6, an artificial ligand to GHS-R. The calcium changes varied in each cell line in relation to the expression levels of GHS-R mRNA.
GHRP-6 is a peptide from the category of growth hormone releasing peptides, ie growth hormone-releasing peptides. The most frequent use of these peptides is an extreme increase in the body's growth hormone production. The main application area of GHRP-6 is an increase in growth hormone levels, which also results in an increase in IGF1 levels. This also radically supports fat loss as well as muscle building. In general, GHRPs are used as an alternative to growth hormones or even combined with growth hormones to achieve virtually a double effect, synthetic and natural. Reasons for favoring GHRP-6 versus other GHRPs are its appetite-stimulating effect, although present, but weaker than GHRP-2 and its ability to reduce inflammation and assist healing of injuries such as tendonitis. Products are sold strictly for research purposes only, not for human consumption!
As with any GHRP or GHRH, administration of GHRP-6 doses should be done no sooner than 2 hours following the last meal containing carbohydrates or fats, and no sooner than 30 minutes prior to the next consumption of carbohydrates or fats. As evidenced by studies referenced in the introduction of this profile, the consumption of fats and carbohydrates will significantly blunt (but not eliminate) HGH release. HGH pulses will generally reach their peak by about 30 minutes following injection, after which it is then acceptable to consume a meal containing carbohydrates and fats.
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used in the management of mild to moderate pain and inflammation in conditions such as dysmenorrhoea, headache including migraine, post-operative pain, dental pain, musculoskeletal and joint disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis including juvenile idiopathic arthritis, peri-articular disorders such as bursitis and tenosynovitis, and soft tissue disorders such as sprains and strains. It is also used to reduce fever.

In studies of the opioid control of GH secretion, several peptide analogues of met-enkephalin were found to be potent GH secretagogues. These include the GH-releasing peptide GHRP-6 (Fig. 7-21), hexarelin (His-d2MeTrp-Ala-Trp-dPhe-Lys-NH2), and other more potent analogues including cyclic peptides and modified pentapeptides. Subsequently, a series of nonpeptidyl GHRP mimetics were synthesized with greater oral bioavailability, including the spiropiperidine MK-0677 and the shorter acting benzylpiperidine L-163,540 (see Fig. 7-21). Common to all these compounds, and the basis of their differentiation from GHRH analogues in pharmacologic activity screens, is their activation of phospholipase C and inositol 1,4,5-trisphosphate. This property was exploited in a cloning strategy that led to the identification of a novel GPCR GHS-R that is highly selective for the GH secretagogue class of ligands. The GHS-R is unrelated to the GHRH receptor and is highly expressed in the anterior pituitary gland and multiple brain areas, including the medial basal hypothalamus, the hippocampus, and the mesencephalic nuclei that are centers of dopamine and serotonin production.
Technically, it is a “protein-peptide hormone” which means that it consists of 70 amino acids bonded together. Just like the peptides I’ve written about in the past, this means that it must be injected, because otherwise IGF-1 simply degrades in the gut, rendering it useless. Your own human growth hormone release promotes the synthesis of IGF-1 in your liver (and to smaller amounts, synthesis of IGF-1 by your muscles), your liver and muscles then synthesize IGF-1 and then, in the case of your liver, subsequently package the IGF-1 with binding proteins for transport into the blood. In a type of anabolic positive-feedback loop, IGF-1 then further increases growth hormone’s anabolic effects.

In a study designed to assess the effect of both the estrogen and GHRP-6 on the cardiovascular and metabolic diseases in ovariectomized (OVX) rats, Elbassuoni, et al found that although GHRP-6 failed to produce significant change in body weight gain and food intake, it clearly reversed the effect of OVX on fasting serum glucose, insulin, insulin resistance, and the assessed lipid fractions. They concluded that the effect of GHRP-6 on improving dyslipidemia after OVX was even more potent than that of estrogen.12 Furthermore, the mechanism of action of GHRP-6 has been more extensively studied in experimental models with obese subjects, and was shown to be a powerful GH releaser in obesity, and to release GH independently of the hypothalamic factors (GHRH and somatostatin).13
The other submission commented on the consideration to place AOD-9604 in Appendix D. The submission supported listing in Schedule 4, but raised concerns that listing the substance in Appendix D would limit any future development work, including clinical trials that are currently being conducted on the substance. The submitter notes that there are currently 5 clinical trials notified to the TGA using this substance , with these approved clinical trials going ahead on the basis that the substance is safe for human use. Inclusion in Appendix D may place unnecessary burden on those conducting these clinical trials.
If GHRP-6 is powerful for growth hormone release, this peptide is even stronger, albeit slightly so. GHRP-2 is used for similar purposes as the other compound. But it does not fire up appetite as the other peptide is known to do. This may make it more ideal for people interested in improving lean muscle mass. Furthermore, it does not desensitize when taken in low doses without observing breaks as required for other peptides.
For those who are just getting started, make sure you go gradually. Start off with an eight-week cycle, and start off with 200 mcg (rather than 300) per day. Doing a test run will allow you to see how your body is going to react. If all goes well, you can then increase your dosage cycle to an 8 to 12 week period, and possibly add an additional injection dose daily, or increase to 300 mcg with each use.
Now these artificially manufactured compounds can replicate certain hormones within the human body to signal or trigger certain effects. Whereas GH (a total protein hormone of 191 amino acids), can attach to receptors at multiple sites within the body to influence different effects (say muscle cells, bone cells and fats cells, to name but three), shorter peptides have been isolated to trigger certain effects in a specific area/s. Imagine it’s like having a full tool box which you can mend a whole car with, but then you take certain tools out for different jobs and keep them apart in separate drawers which do specific jobs…sort of.
Before the discovery of ghrelin, synthetic GH secretagogs were available. Several studies investigated the effects of these substances on human sleep. Oral administration of the GH secretagog MK-677 for 1 week prompts a distinct sleep-promoting effect in healthy young male volunteers, whereas a weak effect is observed in elderly subjects. This study shows that oral administration of a peptide is capable of promoting sleep. After repetitive intravenous administration of GH-releasing peptide 6 (GHRP-6), non-REM sleep stage 2 increases. Similar to the effects of ghrelin in male subjects GH, ACTH, and cortisol are elevated. In a set of studies, the intranasal, oral, and sublingual administration of GHRP-6 was tested. By these routes of administration the effects of the peptide on the sleep EEG and on hormone secretion are less distinct and partly different from those after intravenous injection. In contrast to the sleep-promoting effects of GHRP-6 and ghrelin, hexarelin prompts a decrease of SWS, whereas the pattern of endocrine effects after hexarelin resemble the endocrine changes after ghrelin and GHRP-6 in that there is a marked stimulation of GH. The decrease of SWS after hexarelin may be related to negative feedback inhibition of endogenous GHRH. After a single dose of GHRP-2 during the third period of REM sleep, sleep remains unchanged. The lack of effects in this study may be related to the method that uses only a single injection of the substance.
for teeth whitening products containing between 3 per cent to 6 per cent of hydrogen peroxide and between 9 per cent to 18 per cent of carbamide peroxide to be only legally accessible from a registered health practitioner. Patients to be permitted to use these products 'at home' only after consultation with their registered health practitioner; and

GHRP-6 is normally always manufactured as lyophilized (freeze-dried) powder contained in vials in amounts of 5mg. Some companies might manufacture amounts greater or lesser than 5mg per vial, but the standard is generally 5mg/vial. The lyophilized powder contained within the vial will need to be reconstituted with bacteriostatic water in order for it to be injected. After reconstitution, the solution must then be refrigerated in storage. If left in hot environments or in room temperature environments for extended periods of time, the protein structure will degrade and become ineffective. For reconstitution, users will typically mix 3ml of bacteriostatic water with the powder gently. However, users can and do frequently reconstitute the powder with less (or more) water which will yield different concentrations of GHRP-6. For example, reconstitution of 5mg of powder with 3ml of water will yield GHRP-6 doses of 166mcg per 0.1ml (or 10iu on an insulin syringe).
Because some GHRP’s are equally effective as others in increasing GH but differ in effect on hunger or ACTH stimulation, it seems likely that there may be differences in ghrelin receptors between different tissues, or differences in function (for example with cofactors.) This is the most likely explanation for GHRP-6 being effective in stimulating hunger and helping heal tendinitis, while GHRP-2 stimulates hunger less and may have less value for healing.
Paracetamol/caffeine formulations have a long-established safety and efficacy profile over 25 years of use as an open-sale medicine in major markets around the world. The paracetamol/caffeine combination analgesic was registered as a schedule 2 product in Australia and has been marketed since 2010. Since that time no new significant issues or potential risks have been reported.
Growth hormone releasing peptide (GHRP) 2 is a type of peptide therapeutic that mimics the effects of ghrelin, the “hunger hormone”. Ghrelin is a hormone that helps regulate appetite as well as energy distribution and rate of use, or metabolism. In the 1980’s, ghrelin was discovered to be the body’s natural ligand (or binding molecule) of the GHRP receptor in the anterior pituitary. This was a significant discovery, as it highlighted the role of ghrelin in hGH secretion and growth regulation. Modern biotechnology has used this knowledge to develop peptides that can be administered to mimic ghrelin’s hGH stimulation, but in a more targeted fashion. GHRP 2 is one such peptide, stimulating hGH secretion by 7-15 times, increasing appetite and meal initiation, while also decreasing fat mass and cholesterol. GHRP 2 is ideal for patients who are hypercatabolic, due to critical illness, cancer, AIDS, etc. It should be noted that GHRP 2 can also increase levels of prolactin, aldosterone, and cortisol.
Yes, Ipamorelin can help you lose weight. But, if you are not exercising, and aren’t eating well, it can only do so much. There is no magical supplement which will undo laziness and a horrible diet – keep this in mind. When using it for fat loss, make sure you are exercising. Doing so will naturally increase weight loss results, as you are going to burn more calories, along with the caloric deficit you are already on, for greater results. Further, your diet matters. If you are eating 5000 calories of junk per day, no supplement will help you lose weight – no matter how potent it claims to be!
The other submission commented on the consideration to place AOD-9604 in Appendix D. The submission supported listing in Schedule 4, but raised concerns that listing the substance in Appendix D would limit any future development work, including clinical trials that are currently being conducted on the substance. The submitter notes that there are currently 5 clinical trials notified to the TGA using this substance , with these approved clinical trials going ahead on the basis that the substance is safe for human use. Inclusion in Appendix D may place unnecessary burden on those conducting these clinical trials.

Broadly speaking, it’s long been a widespread view that fasting can in many instances provide healthful effects beyond simple fat loss. It’s speculative to say that increased ghrelin levels must be a major cause of such effect (if granting the effect), but it’s entirely consistent with the scientific literature that such elevation of ghrelin levels may have health benefits. Appropriate-dosed and cycled GHRP use may at least partially provide such benefits, particularly with regard to anti-inflammatory and healing effect.


GHRP-6 is a peptide from the category of growth hormone releasing peptides, ie growth hormone-releasing peptides. The most frequent use of these peptides is an extreme increase in the body's growth hormone production. The main application area of GHRP-6 is an increase in growth hormone levels, which also results in an increase in IGF1 levels. This also radically supports fat loss as well as muscle building. In general, GHRPs are used as an alternative to growth hormones or even combined with growth hormones to achieve virtually a double effect, synthetic and natural. Reasons for favoring GHRP-6 versus other GHRPs are its appetite-stimulating effect, although present, but weaker than GHRP-2 and its ability to reduce inflammation and assist healing of injuries such as tendonitis. Products are sold strictly for research purposes only, not for human consumption!


Furthermore, the most potent profibrogenic growth factors: Tgfb1, Pdgfb, and Ctgf also appeared significantly underexpressed in the GHRP-6-treated wounds (all ) (Figure 4). In line with this, we observed a significant reduction in the expression levels of Col1a1 and Col3a1 (Figure 4, both ). Concomitantly, we addressed the attention to filamentous and contractile proteins associated with fibroblasts and other differentiated mesenchyme-derived cells. Acta2 appeared close to a significant reduction (), whereas Des, Vim, and Fn transcriptional expression appeared significantly reduced (all ), as compared to placebo-treated wounds.
For example, insufficient protein or calories can cause IGF-1 to plummet, while ample calories can cause IGF-1 to increase. For example, one study of women who fed with excess calories over and above their normal metabolic rate noted a 19% increase in IGF-1 after two weeks of overfeeding, with 46% of the weight gain from  lean mass and 54% from bodyfat. Fasting insulin doubled in these women, and testosterone levels also significantly increased.
Ghrelin has been linked to inducing appetite and feeding behaviors. Circulating ghrelin levels are the highest right before a meal and the lowest right after. Injections of ghrelin in both humans and rats have been shown to increase food intake in a dose dependent manner. So the more ghrelin that is injected the more food that is consumed. However, ghrelin does not increase meal size, only meal number. Ghrelin injections also increase an animals’ motivation to seek out food, behaviors including increased sniffing, foraging for food, and hoarding food. Ghrelin also readies the body for the incoming nutrients by stimulating gastrointestinal motility and gastric acid secretions.
[2] Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. V Popovic, S Damjanovic, D Micic, M Djurovic, C Dieguez, and F F Casanueva. JCEM 1995 80: 942-7; doi:10.1210/jc.80.3.942.
If you are interested in order a product you will need to fill out our quick 2-minute Medical Questionnaire. As we provide Schedule 4 medication we require your medical details so our Prescribing Doctor can provide you with the safest and most effective solution for your health and fitness goals. If you have any further questions surrounding our Order Process please feel free to call out Customer Support team to discuss any concerns.
But ever since the 1970’s, scientists have observed that although we produce substantial amounts of both IGF-1 and human growth hormone (HGH) in childhood, these hormones decrease drastically by the time we reach old age. They also noticed that IGF-1 could possibly be manipulated to extend life and to prolong the deteriorating effects of aging (you can read the research here).
Though there are a lot of similarities between the two peptides, there is no denying the fact that they also have vast differences. Besides having differences in the release of growth hormones and stimulation of pituitary glands, GHRP 2 is known to have better control in the release of prolactin and Cortisol. That’s not all; GHRP 2-based supplements are relatively cheaper as compared to other supplements that are available in the market, including the ones that are GHRP-6 based. There are a few individuals that opt for GHRP 6 due to the fact that it has lesser impact on prolactin and Cortisol; at least as compared to GHRP 2.
×